DekaBank Deutsche Girozentrale lessened its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 2.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 118,300 shares of the biotechnology company’s stock after selling 3,100 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Exelixis were worth $2,277,000 as of its most recent filing with the SEC.
A number of other large investors also recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Exelixis by 3.8% during the third quarter. BlackRock Inc. now owns 30,094,004 shares of the biotechnology company’s stock valued at $533,265,000 after purchasing an additional 1,096,629 shares during the period. JPMorgan Chase & Co. grew its holdings in Exelixis by 8.8% during the third quarter. JPMorgan Chase & Co. now owns 5,931,216 shares of the biotechnology company’s stock valued at $105,101,000 after purchasing an additional 480,986 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd grew its holdings in Exelixis by 27.1% during the third quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 4,666,961 shares of the biotechnology company’s stock valued at $82,698,000 after purchasing an additional 995,133 shares during the period. First Trust Advisors LP grew its holdings in Exelixis by 78.6% during the third quarter. First Trust Advisors LP now owns 4,643,726 shares of the biotechnology company’s stock valued at $82,287,000 after purchasing an additional 2,044,201 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Exelixis by 28.1% during the second quarter. Renaissance Technologies LLC now owns 4,037,810 shares of the biotechnology company’s stock valued at $86,894,000 after purchasing an additional 885,000 shares during the period. 77.24% of the stock is owned by institutional investors and hedge funds.
In other news, CEO Michael Morrissey sold 12,501 shares of the business’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $17.82, for a total value of $222,767.82. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director George A. Scangos sold 25,000 shares of the business’s stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $16.85, for a total value of $421,250.00. Following the completion of the transaction, the director now owns 1,561,981 shares in the company, valued at $26,319,379.85. The disclosure for this sale can be found here. Insiders sold 289,367 shares of company stock worth $5,219,346 over the last 90 days. Company insiders own 4.80% of the company’s stock.
Shares of Exelixis stock opened at $21.50 on Tuesday. Exelixis, Inc. has a 52 week low of $13.42 and a 52 week high of $32.20. The stock has a market capitalization of $6.07 billion, a PE ratio of 17.21, a price-to-earnings-growth ratio of 1.20 and a beta of 2.32. The company has a current ratio of 8.66, a quick ratio of 8.54 and a debt-to-equity ratio of 0.01.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.22. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The business had revenue of $225.40 million for the quarter, compared to the consensus estimate of $174.14 million. During the same period in the previous year, the business earned $0.26 earnings per share. The business’s revenue was up 47.8% on a year-over-year basis. On average, equities research analysts anticipate that Exelixis, Inc. will post 1.3 EPS for the current fiscal year.
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Article: Swap
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.